BioNTech SE and Pfizer (PFE) recently received a positive recommendation from the European Medicines Agency for marketing ...

Demand for the jab through the NHS and privately in pharmacies has remained steady since the end of the pandemic ...

Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

Researchers looked at how the vaccine affected patients' corneas - the clear front part of the eye that allows light to come ...

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has ...

A Turkish study finds Pfizer’s COVID-19 vaccine may cause temporary changes in corneal thickness and cell count, raising concerns for those with existing eye issues or transplants.

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced today that the European Medicines Agency's (EMA) Committee for ...

BioNTech's COVID-19 vaccine on one's eye, which could lead an indivual to permanent vision loss. Read on... TheHealthSite.com ...

New York drugmaker Pfizer and Mainz, Germany, immunotherapy company BioNTech said the European Commission, which generally follows CHMP's advice, will now review the recommendation, with a final ...

Paxlovid is an antiviral combination therapy that can reduce the risk of COVID-19 causing severe illness, hospitalization and ...

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...